Acute Bronchitis in Children
Conditions
Brief summary
Any pathogen that causes an upper respiratory tract infection can cause bronchitis.The primary pathogen is virus. On the basis of virus infection, pathogenic bacteria may cause secondary infection or co-infection。Xiyanping injection is mainly used in the treatment of bronchitis by intravenous injection。
Detailed description
To further verify the clinical value and safety of intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children, provide reference for subsequent validation studies, and provide more reasonable and standard application guidance and basis for clinical practice.A multicenter, randomized, parallel controlled study was conducted on the treatment of acute bronchitis by intramuscular injection of Xiyanping injection.
Interventions
Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
Sponsors
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 6 Years
Healthy volunteers
No
Inclusion criteria
1. Age: 1-6 years (\>1 years, ≤6years); 2. Children who meet the diagnosis criteria of acute bronchitis in children; 3. All symptoms, including cough, had been present for less than 72 hours at the time of inclusion screening; 4. The informed consent process complies with the regulations, and the legal guardian signs the informed consent.
Exclusion criteria
1. Have used Chinese medicine injection containing andrographolide and similar functions (clearing heat and detoxifying, relieving cough and stopping dysentery) or oral dosage within 72 hours. 2. Children with severe bronchitis or early pneumonia; 3. Children with acute infectious diseases such as measles, pertussis,influenza and hand-foot-and-mouth disease; 4. Children with diseases such as acute upper respiratory tract infection, suppurative tonsillitis, wheezing bronchitis, bronchial asthma, bronchiolitis pneumonia, tuberculosis, tumor; 5. neutrophil granulocyte\>80%, or those who need antibiotic therapy; 6. Children with severe malnutrition and immunodeficiency; 7. Children with severe primary diseases such as heart, liver, kidney, digestion and hematopoietic system; 8. Allergic constitution and children allergic to the drug used in this study; 9. Children who are taking epinephrine, isoproterenol and other catecholamines; 10. Children who are taking MAO inhibitors or tricyclic antidepressants 11. Children who are taking non-selective β-blockers such as Propranolol; 12. Those who are not included based on the investigators judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total clinical effective rate | up to day 7 | The children were evaluated according to the improvement of body temperature (axillary temperature), cough, expectoration, lung rales and other symptoms and signs and the improvement time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cough easing | up to day 7 | Symptoms are less than or equal to 1 point (mild) and remain for 24 hours or more |
| Lung rales relieved | up to day 7 | Symptoms are less than or equal to 1 point (mild) and remain for 24 hours or more |
| Fever relief | up to day 7 | Body temperature \<37.5℃ (axillary temperature) and maintained for 24h or more |
Outcome results
None listed